Ollin Biosciences
PrivateLast Round
Series B
Jun 24, 2026
Est. Valuation
$500M
Total Funding Raised
$430M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Ollin Biosciences is a biopharmaceutical company that develops therapies for vision-threatening ophthalmic diseases such as wet age-related macular degeneration and diabetic macular edema.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ollin Biosciences Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Ollin Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 24, 2026 | ||||
| Series A | Sep 17, 2025 |
Ollin Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B |
| CPP Investments | Series B |
| RA Capital Management | Series B |
| TCG Crossover | Series B |
| ARCH Venture Partners | Series B, Series A |
| Commodore Capital | Series B |
| Monograph Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 24, 2026
$330M round led by ARCH Venture Partners and TCG Crossover.
- Jan 9, 2026
Drug candidate OLN324 will advance to Phase III trials.
Ollin Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ollin Biosciences's valuation, stock price, and market status.